Crinetics Pharmaceuticals Inc (CRNX) 收益

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 594 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.